argenx SE (NASDAQ:ARGX) Accelerates Label Expansion And Pipeline Readouts Through Mid‑2026
![]() |
argenx enters the immediate period positioned to extend clinical and label momentum, with upcoming regulatory milestones and Phase‑3 readouts driving the near-term narrative. |










